Helicobacter pylori and non-malignant diseases

Helicobacter

Volumn 12, Issue SUPPL. 1, 2007, Pages 20-22

  Rokkas, Theodore ^a   Simsek, Ilkay ^b   Ladas, Spiros ^c  

^a HENRY DUNANT HOSPITAL   (Greece)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

GERD; Non ulcer dyspepsia; NSAIDs; Peptic ulcer disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; CAGA PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROTON PUMP INHIBITOR; RABEPRAZOLE; STOMACH SECRETION INHIBITOR;

ANTIBIOTIC THERAPY; ANTIREFLUX OPERATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG DOSE COMPARISON; DRUG EFFECT; DYSPEPSIA; ECONOMIC ASPECT; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LOW DRUG DOSE; META ANALYSIS; PEPTIC ULCER; PREDICTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; STOMACH ANTRUM; STOMACH INJURY; SYSTEMATIC REVIEW;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; DYSPEPSIA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; TREATMENT OUTCOME;

HELICOBACTER PYLORI;

EID: 34548147285     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2007.00531.x     Document Type: Review

References (11)

1. 2-receptor antagonist until assessment of Helicobacter pylori eradication can reduce recurrence of peptic ulcer after successful eradication of the organism: prospective randomized controlled trial. J Gastroenterol Hepatol 2006 21 : 1048 53.
2. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006 2 : CD003840.
3. Suzuki T, Matsuo K, Sawaki A, et al. Systematic review and meta-analysis: importance of CagA status for successful eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 2006 24 : 273 80.
4. Venerito M, Treiber G, Wex T, Kuester D, Roessner A, Di Mario F, Malfertheiner P. Effects of low-dose aspirin on gastric erosions, cyclooxygenase expression and mucosal prostaglandin-E2 do not depend on Helicobacter pylori infection. Aliment Pharmacol Ther 2006 23 : 1225 33.
5. de Boer W, de Wit N, Geldof H, Hazelhoff B, Bergmans P, Smout A, Tytgat G. Does Helicobacter pylori infection influence response rate or speed of symptom control in patients with gastroesophageal reflux disease treated with rabeprazole? Scand J Gastroenterol 2006 41 : 1147 54.
6. Shimatani T, Moriwaki M, Xu J, Tazuma S, Inoue M. Acid-suppressive effects of rabeprazole: comparing 10 mg and 20 mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers. Dig Liver Dis 2006 38 : 802 8.
7. Vakil N, Talley NJ, Stolte M, Sundin M, Junghard O, Bolling-Sternevald E. Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2006 24 : 55 63.
8. Lundell L, Havu N, Miettinen P, et al. Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther 2006 23 : 639 47.
9. Hu WH, Lam SK, Lam CL, et al. Comparison between empirical prokinetics, Helicobacter test-and-treat and empirical endoscopy in primary-care patients presenting with dyspepsia: a one-year study. World J Gastroenterol 2006 12 : 5010 6.
10. Jarbol DE, Bech M, Kragstrup J, Havelund T, Schaffalitzky de Muckadell OB. Economic evaluation of empirical antisecretory therapy versus Helicobacter pylori test for management of dyspepsia: a randomized trial in primary care. Int J Technol Assess Health Care 2006 22 : 362 71.
11. Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006 2 : CD002096.